US Pharma MarketingCapricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data
After a negative FDA advisory committee vote, Capricor Therapeutics said it will file additional data and analyses on its Duchenne muscular dystrophy therapy in hopes of a better shot at approval in a narrower indication. ...
After a negative FDA advisory committee vote, Capricor Therapeutics said it will file additional data and analyses on its Duchenne muscular dystrophy therapy in hopes of a better shot at approval in a narrower indication.
...
Source: Endpoints News